Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Myriad Genetics (MYGN) Short-Term Debt repayments: 2017-2025

Historic Short-Term Debt repayments for Myriad Genetics (MYGN) over the last 4 years, with Sep 2025 value amounting to $60.0 million.

  • Myriad Genetics' Short-Term Debt repayments rose 200.00% to $60.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $120.0 million, marking a year-over-year decrease of 14.29%. This contributed to the annual value of $119.5 million for FY2024, which is 198.75% up from last year.
  • As of Q3 2025, Myriad Genetics' Short-Term Debt repayments stood at $60.0 million, which was up 192.68% from $20.5 million recorded in Q1 2025.
  • Myriad Genetics' Short-Term Debt repayments' 5-year high stood at $106.4 million during Q3 2021, with a 5-year trough of $19.5 million in Q4 2024.
  • Its 3-year average for Short-Term Debt repayments is $34.3 million, with a median of $20.5 million in 2025.
  • Over the last 5 years, Myriad Genetics' Short-Term Debt repayments had its largest YoY gain of 200.00% in 2025, and its largest YoY loss of 65.83% in 2025.
  • Quarterly analysis of 4 years shows Myriad Genetics' Short-Term Debt repayments stood at $106.4 million in 2021, then reached $40.0 million in 2023, then slumped by 51.25% to $19.5 million in 2024, then spiked by 200.00% to $60.0 million in 2025.
  • Its Short-Term Debt repayments was $60.0 million in Q3 2025, compared to $20.5 million in Q1 2025 and $19.5 million in Q4 2024.